Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence.
Lyu SI, Fretter C, Simon AG, Spielmann SM, Damanakis AI, Zhao Y, Bruns CJ, Schmidt T, Popp FC, Waldschmidt D, Quaas A, Knipper K; PANCALYZE Study Group. Lyu SI, et al. Among authors: simon ag. Transl Oncol. 2024 Sep;47:102044. doi: 10.1016/j.tranon.2024.102044. Epub 2024 Jun 24. Transl Oncol. 2024. PMID: 38917592 Free PMC article.
Dissecting the inflammatory tumor microenvironment of esophageal adenocarcinoma: mast cells and natural killer cells are favorable prognostic factors and associated with less extensive disease.
Dos Santos Cunha AC, Simon AG, Zander T, Buettner R, Bruns CJ, Schroeder W, Gebauer F, Quaas A. Dos Santos Cunha AC, et al. Among authors: simon ag. J Cancer Res Clin Oncol. 2023 Aug;149(10):6917-6929. doi: 10.1007/s00432-023-04650-0. Epub 2023 Feb 24. J Cancer Res Clin Oncol. 2023. PMID: 36826594 Free PMC article.
The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Simon AG, Lyu SI, Laible M, Wöll S, Türeci Ö, Şahin U, Alakus H, Fahrig L, Zander T, Buettner R, Bruns CJ, Schroeder W, Gebauer F, Quaas A. Simon AG, et al. J Transl Med. 2023 Aug 17;21(1):552. doi: 10.1186/s12967-023-04433-8. J Transl Med. 2023. PMID: 37592303 Free PMC article.
Co-expression patterns of cancer associated fibroblast markers reveal distinct subgroups related to patient survival in oropharyngeal squamous cell carcinoma.
Lyu SI, Johannsen J, Simon AG, Knipper K, Wuerdemann N, Sharma SJ, Thelen M, Hansen KK, Fretter C, Klasen C, Esser J, Suchan MC, Abing H, Zimmermann PH, Schultheis AM, Schloesser HA, Klussmann JP, Quaas A, Eckel HNC. Lyu SI, et al. Among authors: simon ag. Front Cell Dev Biol. 2024 Jan 24;12:1337361. doi: 10.3389/fcell.2024.1337361. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38328551 Free PMC article.
Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma.
Knipper K, Hussein Y, Simon AG, Fretter C, Damanakis AI, Zhao Y, Bruns CJ, Schmidt T, Popp FC, Quaas A, Lyu SI; PANCALYZE Study Group. Knipper K, et al. Among authors: simon ag. J Cancer Res Clin Oncol. 2024 Mar 19;150(3):137. doi: 10.1007/s00432-024-05681-x. J Cancer Res Clin Oncol. 2024. PMID: 38502354 Free PMC article.
Hexokinase 2 as an independent risk factor for worse patient survival in esophageal adenocarcinoma and as a potential therapeutic target protein: A retrospective, single‑center cohort study.
Lyu SI, Simon AG, Jung JO, Fretter C, SchrÖder W, Bruns CJ, Schmidt T, Quaas A, Knipper K. Lyu SI, et al. Among authors: simon ag. Oncol Lett. 2024 Aug 13;28(4):495. doi: 10.3892/ol.2024.14628. eCollection 2024 Oct. Oncol Lett. 2024. PMID: 39211305 Free PMC article.
34 results